The big question is what are the assets worth and who has bought these assets. They are well worth buying to so many large clients to get a drug with so much potential at phase 3 with orphan drug status. Yikes. Worth way more than this. However that only the way I see it. Hoping big Pharma does too. They have so many connections from previous activity. Just takes that one release and it’s off to the races for Nspx . Without it we are probably dust
News 
Market Data 
Discover 
